Atrial fibrillation and heart failure with preserved ejection fraction: diagnostic challenges and therapeutic opportunities
Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterised by cardiac and non-cardiac physiologic disturbances, commonly underpinned by cardiometabolic abnormalities, which culminate in elevated left ventricular filling pressures and progressive symptoms of exercise intolerance. Arrhythmias, particularly atrial fibrillation (AF), are common in HFpEF and have important clinical implications. AF complicates the diagnosis and management of HFpEF. In this review, we synthesise the impact of AF on disease detection, symptom burden and prognosis and HFpEF treatment. Furthermore, we review pharmacological and interventional therapies that may mitigate the risk of AF and improve how patients with HFpEF feel, function and survive.
Authors
- Faro R. Verelst
- Andreas B. Gevaert (ORCID: https://orcid.org/0000-0002-1338-4133)
- Harriette G C van Spall
- F Z Ahmed
- Klaus K Witte
Institutions
- University of Antwerp (BE)
- Leeds Teaching Hospitals NHS Trust (GB)
- Queen Elizabeth II Health Sciences Centre (CA)
- Population Health Research Institute (CA)
- Clinical Research Institute (US)
- Antwerp University Hospital (BE)
- Baim Institute for Clinical Research (US)
- Duke Medical Center (US)
- Impact (CA)
- Keele University (GB)
- McMaster University (CA)
Publication Details
- Journal
- Heart
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1136/heartjnl-2025-326954
- Citations
- 1
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 30.07